Current Heart Failure Reports

, Volume 9, Issue 2, pp 92–100

TNF Revisited: Osteoprotegerin and TNF-related Molecules in Heart Failure

  • Thor Ueland
  • Arne Yndestad
  • Christen P. Dahl
  • Lars Gullestad
  • Pål Aukrust
Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (SD Katz, Section editor)

DOI: 10.1007/s11897-012-0088-6

Cite this article as:
Ueland, T., Yndestad, A., Dahl, C.P. et al. Curr Heart Fail Rep (2012) 9: 92. doi:10.1007/s11897-012-0088-6
  • 323 Downloads

Abstract

The pathophysiological role of tumor necrosis factor (TNF) in myocardial failure has been extensively examined in experimental and clinical studies. Recent studies suggest that other members of the TNF/TNF receptor superfamily (TNFSF/TNFRSF) also may play a pathogenic role in chronic HF. TNF ligands, and in particular members of the TNFRSF, are expressed by a wide variety of cells, including myocardial cells. By activating the nuclear factor-κB (NF-κB) and death-related pathways, TNF ligands can induce a variety of effects within the myocardium, including apoptosis, hypertrophy, inflammation, and extracellular matrix remodeling. Among several TNFSF members that have been shown activated in HF, the OPG/RANK/RANKL (osteoprotegerin/receptor activator of NF-κB/RANK ligand) axis may be of importance in the pathogenesis of this disorder through different mechanisms. In this paper, we revisited the role of TNFSF/TNFRSF in the pathophysiology of HF, possibly representing new targets for therapy as well as new biomarkers in this disorder.

Keywords

TNF Tumor necrosis factor Heart failure Inflammation Apoptosis Cardiac hypertrophy Extracellular matrix remodeling Osteoprotegerin OPG Biomarker Pathophysiology 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Thor Ueland
    • 1
  • Arne Yndestad
    • 2
  • Christen P. Dahl
    • 3
  • Lars Gullestad
    • 3
  • Pål Aukrust
    • 4
  1. 1.Research Institute of Internal Medicine, Faculty of Medicine, RikshospitaletOslo University HospitalOsloNorway
  2. 2.Research Institute of Internal Medicine, Center for Heart Failure ResearchUniversity of OsloOsloNorway
  3. 3.Research Institute of Internal Medicine, Department of Cardiology, Center for Heart Failure ResearchUniversity of OsloOsloNorway
  4. 4.Research Institute of Internal Medicine, Section of Clinical Immunology and Infectious Diseases, Faculty of MedicineUniversity of OsloOsloNorway